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Abstract
The results of the recent Step Study highlight a need to clarify the effects of pre-existing natural immunity to a vaccine
vector on vaccine-induced T-cell responses. To investigate this interaction, we examined the relationship between pre-
existing Ad5 immunity and T-cell cytokine response profiles in healthy, HIV-uninfected recipients of MRKAd5 HIV-1 gag
vaccine (HVTN 050, ClinicalTrials.gov #NCT00849732). Participants were grouped by baseline Ad5 neutralizing antibody
titer as either Ad5-seronegative (titer #18; n=36) or Ad5-seropositive (titer .200; n=34). Samples from vaccine recipients
were analyzed for immune responses to either HIV-1 Gag peptide pools or Ad5 empty vector using an ex vivo assay that
measures thirty cytokines in the absence of long-term culture. The overall profiles of cytokine responses to Gag and Ad5
had similar combinations of induced Th1- and Th2-type cytokines, including IFN-c, IL-2, TNF-a, IP-10, IL-13, and IL-10,
although the Ad5-specific responses were uniformly higher than the Gag-specific responses (p,0.0001 for 9 out of 11
significantly expressed analytes). At the peak response time point, PBMC from Ad5-seronegative vaccinees secreted
significantly more IP-10 in response to Gag (p=0.008), and significantly more IP-10 (p=0.0009), IL-2 (p=0.006) and IL-10
(p=0.05) in response to Ad5 empty vector than PBMC from Ad5-seropositive vaccinees. Additionally, similar responses to
the Ad5 vector prior to vaccination were observed in almost all subjects, regardless of Ad5 neutralizing antibody status, and
the levels of secreted IFN-c, IL-10, IL-1Ra and GM-CSF were blunted following vaccination. The cytokine response profile of
Gag-specific T cells mirrored the Ad5-specific response present in all subjects before vaccination, and included a number of
Th1- and Th2-associated cytokines not routinely assessed in current vaccine trials, such as IP-10, IL-10, IL-13, and GM-CSF.
Together, these results suggest that vector-specific humoral responses may reduce vaccine-induced T-cell responses by
previously undetected mechanisms.
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Introduction
Most T-cell-targeted HIV vaccine candidates are based on
vectors derived from naturally occurring human viruses, and pre-
existing immunity to these viruses has the potential to negatively
impact the desired vaccine response. For instance, the recent Step
Study HIV T-cell vaccine test-of-concept/efficacy trial unexpect-
edly showed that vaccine recipients who had pre-existing
neutralizing antibodies against the vaccine’s non-replicating
adenovirus serotype 5 (Ad5) vector trended toward having an
increased risk of HIV-1 infection [1]. While it has been shown that
Ad5-specific antibodies blunt the desired immune response to an
Ad5-based vaccine in a dose-dependent manner [2,3,4], it remains
unclear how this may translate into an increased risk of HIV-1
infection.
Ad5-specific antibodies limit the dose and duration of target cell
exposure to Ad5-vaccine viral particles, which lower immune
responses by reducing the frequency of transduced cells [3]. Such
restriction is particularly vexing because Ad5 seropositivity rates
tend to be higher in populations with higher risks of HIV infection
[5,6]. Blunting of a vaccine response due to neutralizing antibodies
can be partially overcome by increasing the dose or number of
inoculations [3,6], but even with such dose optimization, rates of
HIV-specific IFN-c T-cell responses induced by Ad5/HIV-1
vaccination remain higher in vaccine recipients with lower Ad5
neutralizing antibody titers [1,2]. However, in the Step Study, the
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vaccine recipients who were positive for Ad5 neutralizing
antibodies, suggesting that lower IFN-c response rates cannot be
solely responsible for the increased trend in infection rates for Ad5-
seropositive vaccine recipients. In addition, in vitro studies indicate
that vector-specific antibodies can enhance trans infection of T cells
by HIV-1 via the formation of immune complexes [7] and Ad5-
specific CD4
+ T-cell proliferative responses correlate with
increased expression of mucosal homing markers [8], but evidence
for such an interaction in vivo remains to be demonstrated.
Antiviral T-cell responses are not comprised of a single function
and often include the simultaneous production of multiple
cytokines, which can indicate varying capacities for proliferative,
immunostimulatory, and cytotoxic effector functions [9,10,11,12].
Comparisons between infected cases and non-infected matched
controls among Step Study vaccine recipients showed no
significant differences in terms of HIV-specific T-cell IFN-c, IL-
2, and TNF-a responses by T-cell subset, breadth, magnitude, or
polyfunctional profile [2]. In addition, no differences were
observed between these groups in the frequency of total peripheral
CD4
+CCR5
+ T cells or activated Ki67
+Bcl-2
2 HIV-1 target cells.
However, lower Ad5-specific CD4
+ T-cell responses were detected
in HIV-1-infected cases when compared to non-infected matched
controls [2]. Thus, even though polyfunctional T cells have been
correlated with favorable HIV-1 disease outcomes [13], reliable
correlates of immune protection remain elusive.
Based on the lower Ad5-specific CD4
+ T-cell response rates
observed in Step Study cases and the lack of observed differences
in HIV-specific T-cell responses, we hypothesized that pre-existing
Ad5-neutralizing antibody titers influence vaccine-induced cyto-
kine production of HIV-1- and Ad5-specific responses, but that
current multi-parameter flow cytometric techniques may not be
sufficient to measure these differences. Since characterizing T-cell
responses by flow cytometry is presently limited to concurrent
measurement of four intracellular cytokines [14], we devised a
novel T-cell response assay to simultaneously measure thirty
secreted factors from ex vivo-stimulated peripheral blood mononu-
clear cells (PBMC) without clonal expansion. By using multiplexed
bead arrays to explore T-cell cytokine responses, we could
concurrently measure factors linked to a variety of immune
functions, such as Th1, Th2, pro-inflammatory, and chemotactic
responses. Using this method, we examined the cellular immune
responses of Ad5-seronegative and Ad5-seropositive volunteers
pre- and post-vaccination with a MRKAd5 HIV-1 gag vaccine
similar to the one evaluated in the Step Study. We determined that
Ad5-specific immunity contributes significantly to the vaccine-
induced response, and that certain factors of the T-cell response




All volunteers provided informed written consent prior to
enrollment in the HVTN 050 clinical trial (ClinicalTrials.gov
#NCT00849732). The trial was approved by the institutional/
human subjects review boards of the sponsor institutions and the
trial clinical sites: Hospital Escola Sa ˜o Francisco de Assis (Rio de
Janeiro, Brazil), Centro de Referencia e Treinamento (Sa ˜o Paulo,
Brazil), Federal University of Sao Paulo (Sa ˜o Paulo, Brazil),
Cornell–GHESKIO (Port-au-Prince, Haiti), IMPACTA (Lima,
Peru ´), Maternal Infant Studies Center (San Juan, Puerto Rico),
Research Institute for Health Sciences (Chiang Mai, Thailand),
Mahidol University (Bangkok, Thailand), AFRIMS (Bangkok,
Thailand). University of Alabama at Birmingham (Birmingham,
AL, USA), San Francisco Department of Public Health (San
Francisco, CA, USA), Johns Hopkins University (Baltimore, MD,
USA), University of Maryland at Baltimore (Baltimrore, MD,
USA), Brigham & Women’s Hospital (Boston, MA, USA), Fenway
Community Health (Boston, MA, USA), Harvard University/
Brown University (Boston, MA, USA), Saint Louis University
School of Medicine (St. Louis, MO, USA), New York Blood
Center, Columbia University (New York City, NY, USA),
University of Rochester Medical Center (Rochester, NY, USA),
Vanderbilt University (Nashville, TN, USA) and Fred Hutchinson
Cancer Research Center/University of Washington (Seattle, WA,
USA).
Study population and vaccine regimen
HIV-uninfected individuals between the ages of 19 and 50 years
old were enrolled in a multi-center, double-blind, placebo-
controlled HIV-1 vaccine trial of the MRKAd5 HIV-1 gag
monovalent vaccine candidate, the results of which have been
previously reported [15]. This vaccine contained a non-replicating
Ad5 vector based on an adenovirus Group C strain with the E1
region replaced with a clade B codon-optimized HIV-1CAM-1 gag
sequence [16,17,18]. Participants randomized to the vaccine arm
received either 10
9 or 10
10 viral particles of the MRKAd5 HIV-1
gag vaccine intramuscularly at 0, 4, and 26 weeks. After study
unblinding, vaccine recipients (n=70) who mounted vaccine-
induced IFN-c-secreting Gag-specific T-cell responses were
chosen, as determined by IFN-c ELISpot at 30 weeks after the
first vaccination (median, 352 spot forming cells (SFC)/10
6
PBMC; interquartile range (IQR), 56–2481). The vaccinated
subjects were stratified into two groups based upon their pre-
immunization (baseline) Ad5 neutralizing antibody titer: partici-
pants with baseline Ad5 neutralizing antibody titers #18 (n=36)
defined as the Ad5-seronegative group, while those with baseline
Ad5 neutralizing antibody titers .200 (n=34) were defined as the
Ad5-seropositive group. The two Ad5-serostatus groups were
matched in regard to the number of subjects included who
received either 10
9 or 10
10 viral particles dose of vaccine (30% 10
9
VPU vs. 70% 10
10 VPU). The population demographics for the
test groups used in this study are shown in Table 1.
In addition, assay validation procedures were conducted in
PBMC from chronically HIV-1-infected (n=5) and HIV-1-
uninfected (n=24) volunteers. The HIV-seropositive control
samples were selected based on previously detected Gag-specific
IFN-c ELISpot responses, whereas the HIV-seronegative control
samples were isolated from HIV-1 low-risk, healthy volunteers.
These studies were approved by the institutional human subjects
review board at each clinical site prior to study initiation, and all
vaccine recipients and control group subjects provided a written
informed consent prior to participation.
Sample collection and Ad5 serology
Anticoagulated blood from vaccine recipients was collected by
venipuncture into standard EDTA collection tubes, and PBMC
were isolated on a density gradient and cryopreserved on the day
of collection as previously described [19]. PBMC were collected
for immunogenicity testing prior to vaccination (baseline) and at
peak time points (28 and 30 weeks after the first vaccination).
Serum samples were collected for Ad5 serology testing at a pre-
vaccination screening visit and at 4-, 8-, 12-, 30-, 42-, and 78-week
time points after administration of the first vaccine dose. Ad5
neutralizing antibody titers in serum were determined #45 days
prior to the first immunization as previously described [6].
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Unfractionated PBMC were assayed by a validated IFN-c
ELISpot assay as previously described [20], using overlapping 15-
mer peptide pools based on the homologous HIV-1 gag vaccine
sequence to determine antigen-specific responses. Results were
reported as the number of spot forming cells (SFC) per 10
6 input
cells. Positive responses were defined as $55 SFC/10
6 cells and a
$4-fold response over negative control wells.
Ex vivo multiplex cytokine assay
Cryopreserved PBMC from vaccinees were thawed and
incubated overnight at 37uC, 5% CO2, and 95% humidity in
R10 media (RPMI 1640 [Invitrogen, San Diego, CA] supple-
mented with 10% fetal bovine serum [Gemini Bio-Products, West
Sacramento, CA], 2 mM L-glutamine, 100 U/ml penicillin, and
100 mg/ml streptomycin [Invitrogen]). Cells were plated the
following day in triplicate at a concentration of 2610
5 cells/well
in round-bottom plates. PBMC were stimulated with either 1mg/
ml of pooled 15-mer peptides representing the potential T-cell
epitopes (PTE) present in all global Gag sequences [21], a non-
replicating E1/E3 deletion mutant of Ad5 at an MOI of 25,000, or
an equivalent volume of DMSO, and were incubated for 48 hours,
after which supernatants were collected, aliquoted, and frozen at
280uC. This incubation time was pre-determined to be optimal
for detecting maximal expression of the analytes being measured
while minimizing loss due to in vitro consumption (data not shown).
Cytokines and chemokines were quantified using a Human
Lincoplex 30-plex bead array kit (Linco, St. Charles, MO)
modified from the manufacturer’s instructions to provide higher
statistical power for curve fitting algorithms by applying a
nine-point standard curve rather than the recommended six-point
standard curve (see Table 2 for a complete list of the thirty
cytokines and chemokines analyzed). Data were collected using a
Luminex 200 system (Perkin Elmer, Wellesley, MA) with MiraiBio
Masterplex acquisition and analysis software (Hitachi Software
Engineering, South San Francisco, CA). A five-parameter logistic
curve fit was used with 1/Y weighting to establish analyte-specific
concentrations. The geometric mean of the triplicate control wells
was used as a measure of background for calculating either the
fold-change or background-subtracted concentration for each
participant and stimulation condition.
To validate the specificity of this assay, we measured the 30-plex
cytokine response of HIV-1 Gag-stimulated PBMC from 24
healthy, HIV-seronegative volunteers (n=19 from vaccine trials,
n=5 HIV-seronegative controls; 47% [9/19] male; median age,
32 years [IQR, 25-41]). Using this dataset, we determined analyte-
specific positivity cut-points corresponding to an observed 10%
false-positive-rate for the fold-change over background for each
measured cytokine. Positivity cut-points related to a 10% false
positive rate were unable to be established for IL-5 and fractalkine
due to low response levels; therefore, the response rates for these
two analytes were not calculated. To assess the sensitivity of this
procedure using these positivity cut-offs, we measured the
production of IFN-c in PBMC samples from five HIV-infected
individuals with known HIV-1 Gag-specific T-cell specificities;
after applying our pre-determined IFN-c positivity cut-off we
observed a 100% true-positive rate in this group. Finally, we
confirmed Luminex-determined concentrations of IFN-c and IP-
10 by ELISA in a subset of samples (R&D Systems, Minneapolis,
MN).
Table 1. Demographic characteristics of study populations.
Ad5-seronegative (n=36) Ad5-seropositve (n=34) p-value
1
Median Age (range) 31 (19–47) 27 (19–49) 0.33
Gender n, (%) 0.16
Male 24 (66.7) 17 (50.0)
Female 12 (33.3) 17 (50.0)
Race/Ethnicity n, (%) 0.001
Caucasian 19 (52.8) 10 (29.4)
African/Black 6 (16.7) 3 (8.8)
Asian 1 (2.8) 14 (41.2)
Hispanic 7 (19.4) 4 (11.8)
Other 3 (8.3) 3 (8.8)
Region n, (%) 0.001
U.S. 21 (58.3) 8 (23.5)
Thailand 1 (2.8) 13 (38.2)
S. America 10 (27.8) 10 (29.4)
Caribbean 4 (11.1) 3 (8.8)
Median IFN-c secreting cells
2 0.42
SFC/10
6 PBMC (range) 362 (56–2481) 292 (75–1179)
Median nAb Ad5 Titer (range)
Pre-vaccination #18 (2) 515 (2172$4608) ,0.0001
Peak response 447 (262$4608) 2821 (4882$4608) ,0.0001
1Wilcoxon rank-sum test used for age, ELISpot and Ad5 titer comparisons; Chi-square test used for comparing race/ethnicity and region.
2ELISpot results exclude two Ad5-naı ¨ve and seven Ad5-immune vaccinees due to the use of alternate peptide pools for stimulations.
doi:10.1371/journal.pone.0018526.t001
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Statistical analyses were performed using SAS version 9.1.3 and
JMP version 7.0 (SAS Institute, Cary, NC). Differences between
Ad5 neutralizing antibody test groups (seronegative vs. seropos-
itive) were tested using Wilcoxon rank tests, whereas comparisons
of stimulations within the same individual were tested by Wilcoxon
signed rank tests. Fisher’s exact test was used to compare response
rates, and Kruskal-Wallis was used to compare differences
between stimulation conditions across analytes. All statistical
comparisons were two-sided with an alpha level of 0.05. Only
descriptive statistics were provided whenever a comparison group
had less than five data points. Due to the exploratory nature of this
study, all reported p-values were not subject to multiple
comparison adjustments. However, to assess the impact of multiple
comparisons on these reported results, we performed multiplicity
adjustments by permutation or Hochberg methods to control the
overall type I error (adjusted p-values not shown).
Results
Study Population and Multiplex Cytokine Assay
Performance
The distributions of age and gender were well-matched between
the two study groups (Table 1), but the Ad5-seronegative group
had higher numbers of White participants compared to the Ad5-
seropositive group (52.8% vs. 29.4%, p=0.001 for all ethnicities).
Table 2. Response rate and magnitude of response to Gag peptides or Ad5 empty vector at peak timepoint after three vaccine
doses.









Th1-type IFN-c 48 (86) 55 (98) 5 (1–15) 134 (69–276) 280 (163–493) ,0.001 ,0.001
IL-2 49 (88) 56 (100) 3 (1–5) 33 (21–60) 81 (51–113) ,0.001 ,0.001
TNF-a 36 (64) 42 (75) 18 (12–41) 44 (25–60) 43 (30–75) ,0.001 ,0.001
IL-7 26 (46) 30 (54) 17 (14–26) 22 (19–26) 22 (18–26) ,0.001 ,0.001
IL-15 8 (14) 2 (4) 1 (1–2) 6 (4–9) 2 (1–3) 0.008 NA
sCD40L 26 (46) 44 (79) 1 (1–4) 13 (9–19) 33 (23–50) ,0.001 ,0.001
Th2-type IL-4 8 (14) 10 (18) 1 (1–17) 15 (8–17) 20 (14–30) 0.25 0.002
IL-5 NA NA NA NA NA NA NA
IL-13 40 (71) 50 (89) 3 (1–8) 37 (22–67) 60 (43–88) ,0.001 ,0.001
Immuno-
modulatory
IL-10 29 (52) 53 (95) 73 (48–173) 128 (100–155) 605 (344–953) 0.5 ,0.001
IL-17 19 (34) 32 (57) 2 (1–3) 4 (3–5) 5 (3–6) 0.012 ,0.001
IL-1Ra 21 (38) 41 (73) 296 (179–426) 633 (318–1101) 681 (477–1391) ,0.001 ,0.001
IL-12p40 4 (7) 0 (0) 15 (1–30) 16 (9–22) NA NA NA
IL-12p70 6 (11) 4 (7) 1 (1–1) 1 (1–2) 1 (0–2) 0.13 NA
Pro-
inflammatory
IL-1a 23 (41) 20 (36) 44 (28–88) 87 (65–131) 82 (57–98) 0.13 0.021
IL-1b 24 (43) 27 (48) 13 (5–56) 10 (5–22) 6 (3–12) ,0.001 ,0.001
IL-6 15 (27) 15 (27) 172 (63–3684) 562 (162–3218) 584 (133–1947) 0.98 0.19
Chemokines IL-8 33 (59) 29 (52) 8036 (6228–9705) 9001 (7707–10000) 9675 (8671–10000) ,0.001 ,0.001
MIP-1a 14 (25) 29 (52) 299 (10–1389) 66 (28–718) 133 (91–378) 0.14 0.62
MIP-1b 27 (48) 33 (59) 179 (103–545) 328 (190–485) 524 (357–704) 0.036 0.019
RANTES 1 (2) 9 (16) 470 (470–470) 51 (51–51) 49 (34–165) NA 0.36
IP-10 56 (100) 54 (96) 18 (6–43) 810 (239–1764) 955 (289–2022) ,0.001 ,0.001
MCP-1 11 (20) 12 (21) 1707 (687–3864) 5416 (3707–10000) 4490 (3575–7574) 0.019 ,0.001
Fractalkine NA NA NA NA NA NA NA
Eotaxin 1 (2) 0 (0) 11 (11–11) 8 (8–8) NA 1.0 NA
Growth factors G-CSF 22 (39) 16 (29) 59 (25–247) 128 (67–278) 145 (46–430) 0.003 0.56
GM-CSF 39 (70) 47 (84) 28 (21–69) 78 (50–136) 76 (55–114) ,0.001 ,0.001
EGF 6 (11) 4 (7) 5 (1–6) 5 (4–6) 1 (1–3) 0.56 NA
TGF-a 21 (38) 20 (36) 3 (1–5) 4 (3–7) 6 (3–8) 0.002 0.23
VEGF 18 (32) 26 (46) 10 (3–34) 13 (9–23) 19 (16–25) 0.77 0.61
1Bold denotes analytes with $50% response rate to either Gag or Ad5 with concentrations significantly 2-fold higher or lower than controls.
2Wilcoxon sign-rank two-tailed test using responders when n $5 for each group.
Abbreviations: NA, not applicable.
doi:10.1371/journal.pone.0018526.t002
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alence of adenovirus serotype 5 inside versus outside the U.S. [22].
Peak T-cell responses were measured by IFN-c ELISpot in
PBMC isolated at 30 weeks after the first vaccination (4 weeks after
the third vaccination) as part of the immunogenicity measure-
ments of the phase I protocol. The study population had a median
of 352 SFC/10
6 PBMC, and the medians of the Ad5-seronegative
and Ad5-seropositive groups were not significantly different (362
vs. 292 SFU/10
6 PBMC, respectively; p=0.42). To gain a
broader understanding of vaccine-induced T-cell responses, we
tested these samples for thirty secreted cytokines in response to
Gag peptide stimulation using a multiplex cytokine assay that we
developed. When we compared the IFN-c response rates of the
IFN-c ELISpot and multiplex cytokine assays, we noted that 86%
(48/56) of positive responders in the IFN-c ELISpot assay had
IFN-c-secreting T cells detected by the multiplex cytokine assay
(Table 2). The discordant results between the two assays may
reflect a lower response frequency due to using different Gag
peptide pools in each assay (Gag PTE peptides in the multiplex
assay vs. homologous Merck peptides in the ELISpot assay), and
also because the detection of individual IFN-c-secreting cells by
ELISpot may not absolutely correspond to extracellular protein
secretion measured from multiple cells in a well.
MRKAd5 HIV-1 gag vaccine produces a mixed Th1 and
Th2 response profile of 11 cytokines in restimulated
PBMC
We observed a wide range of T-cell response rates to Gag
peptide pools at the peak time point across the thirty analytes
tested. For example, all vaccine recipients tested had Gag-specific
T cells that secreted IP-10, whereas T cells from only 2% (1/56) of
participants with a Gag-specific response produced Regulated
upon Activation, Normal T cell Expressed and Secreted protein
(RANTES) or eotaxin (median response rate across analytes, 38%;
IQR, 10.3-53.6%; see Table 2). After excluding responses below
the positivity cut-off, the median magnitude of response over
background (fold change) for the remaining vaccine recipients was
highest for IP-10 (1.43 log10) and lowest for RANTES (21.19
log10; Figure 1A, upper panel).
We focused our analysis on those analytes secreted by antigen-
specific (Gag or Ad5) T cells that were detected in at least 50% of
subjects with a significant difference of at least two-fold levels over
or under background (Table 2, boldface). Based on these criteria,
we identified a subset of eleven cytokines that were significantly
expressed in this assay. Within this focus set, the greatest T-cell
responses to Gag were the Th1-associated cytokines IP-10, IFN-c,
and IL-2, all which were detected in 86–100% of vaccine
recipients tested. The Th2-associated cytokine IL-13 showed a
median 12-fold increase in secretion over background in 71% of
vaccine recipients, but the other Th2-associated cytokines, IL-4
and IL-5, were both below the level of detection. In addition, we
found that following Gag stimulation, sCD40L, GM-CSF, TNF-a,
IL-1Ra, IL-17, MIP-1b, and IL-10 were increased by 2-to-10-fold
over background, with response rates of 34-70% (Table 2 and
Figure 1A, upper panel). These results suggest that previously
unrecognized immune factors associated with both Th1 and Th2
responses may contribute to the memory T-cell response induced
by Ad5-HIV-1 vaccination.
Higher IL-10 secretion distinguishes Ad5-specific from
Gag-specific responses to vaccination
When evaluating PBMC from vaccine recipients in the
multiplex cytokine assay, we found higher cellular response rates
were produced by stimulation with Ad5 vector than with Gag
peptides (Table 2). The overall response rate to Ad5 across all
thirty analytes was 48% versus 40% to Gag peptides (Fisher’s exact
p,0.0001), and this difference in response rate was more evident
when we limited the analysis to the previously-defined focus set of
eleven analytes (82% Ad5-stimulated vs. 63% Gag-stimulated,
Fisher’s exact p,0.0001). In addition, compared to Gag-
stimulation, Ad5 empty vector produced a significantly higher
magnitude of response (p,0.0001) in every analyte of the focus set
except for IP-10 (p=0.53) and GM-CSF (p=0.15) (Figure 1B).
Although cytokine profiling results showed that PBMC from
vaccine recipients respond to both the insert and the vector with
similar cytokine production profiles, Ad5 stimulation of PBMC
produced significantly higher amounts of IL-10 than Gag
stimulation. Therefore, we performed an overall test of the
difference between Ad5- and Gag-specific responses between the
eleven focus set analytes and observed a significant difference
(Kruskal-Wallis, p,0.0001), with the difference in IL-10 secretion
between Ad5- and Gag-stimulated PBMC representing the
greatest difference (mean difference=log10(0.72), SD=0.30)
compared to the other 10 analytes (range of mean difference=-
log10(0.02)2log10(0.42)).
Ad5- and Gag-specific IP-10 responses correlate with Ad5
serostatus
To determine the effects of pre-existing Ad5 neutralizing
antibodies on Gag-specific responses, we compared the secreted
amounts of Gag-induced cytokines and chemokines in the Ad5-
seronegative and Ad5-seropositive test groups. Gag-stimulated
PBMC from the Ad5-seronegative group secreted more than twice
as much IP-10 as compared to the Ad5-seropositive group (median
1321 vs. 498 pg/ml, p=0.008) (Figure 2A). In addition, Gag-
stimulated PBMC from the Ad5-seronegative group, compared to
the Ad5-seropositive group, secreted twice as much MIP-1b
(160 pg/ml vs. 80 pg/ml, respectively), but this finding was not
statistically significant (p=0.08). When we measured the concen-
tration of Ad5-specific cytokine secretions at the peak timepoint,
we observed nearly four times as much IP-10 produced by PBMC
from Ad5-seronegative as compared to Ad5-seropositive vaccinees
(median concentration,1622 vs. 433 pg/ml; p=0.0009; Figure 2B).
Furthermore, in addition to the difference we observed for IP-10,
Ad5 empty vector stimulation produced significantly higher
concentrations of IL-2 and IL-10 in PBMC from the Ad5-
seronegative group when compared to the Ad5-seropositive group
(median 98 vs. 65 pg/ml; p=0.005 and 545 vs. 342 pg/ml;
p=0.05, respectively). Likewise, following Ad5 stimulation, twice
as much MIP-1b was seen in the Ad5-seronegative as compared to
the Ad5-seropositive group (median 417 vs. 173 pg/ml, respec-
tively), but this result was again not significant (p=0.07). Taken
together, these data suggest that the presence of pre-existing Ad5-
neutralizing antibody titers may have a blunting effect that is
qualitatively different for Ad5-specific immunity than for Gag-
specific immunity.
Ad5-specific cellular responses are detectable in the
absence of Ad5 neutralizing antibodies
To determine if the Ad5-specific responses we observed in
PBMC from Ad5-seronegative vaccine recipients were due
primarily to the effects of vaccination with MRKAd5 HIV-1 gag,
PBMC collected prior to vaccination were stimulated with Ad5
empty vector. We selected a subset of volunteers with sufficient
available baseline samples (total n=25: Ad5-seronegative, n=17;
Ad5-seropositive, n=8) and included individuals in the peak time
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PLoS ONE | www.plosone.org 5 April 2011 | Volume 6 | Issue 4 | e18526Figure 1. Peak vaccine response to Gag insert and Ad5 vector measured by ex vivo multiplex cytokine assay. Unfractionated PBMC
from vaccinees collected at the peak response time point were assayed for 30 different cytokines and chemokines by multiplex bead array. Results
are expressed as the log10 fold change in concentration compared to negative control wells. (A) Overall response profile of Ad5-seronegative (n=28,
blue dots) and Ad5-seropositive (n=28, red dots) vaccinees to Gag (top) and Ad5 (bottom) for all analytes assayed. Non-responders are shown in
gray. Box plots indicate interquartile ranges and medians for responders only, and medians are connected by the green line for profile comparison.
(B) Comparison of the magnitude of up-regulation of the analyte focus set (selection criteria described in the text) in response to either Gag or Ad5.
Groups were compared by Wilcoxon sign-rank. Horizontal lines denote median values.
doi:10.1371/journal.pone.0018526.g001
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PLoS ONE | www.plosone.org 6 April 2011 | Volume 6 | Issue 4 | e18526Figure 2. Comparison of Gag- and Ad5-specific cellular responses in Ad5-seronegative and Ad5-seropositive vaccinees. PBMC from
vaccinees collected at a peak timepoint (28 weeks) were tested by multiplex cytokine assay. Background-subtracted concentrations of a focus set of
eleven analytes are shown for Ad5-seronegative (blue) and Ad5-seropositive (red) test groups stimulated by either (A) a Gag PTE peptide pool or (B)
Ad5 empty vector. Only positive responders, as reported in Table 2, were included in the analyses. Box and whisker plots indicate median and
interquartile ranges, and groups were compared by Wilcoxon rank sums. Probability estimates are indicated when p#0.05.
doi:10.1371/journal.pone.0018526.g002
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PBMC from 92% (23/25) of donors collected at this pre-
immunization time point (Figure 3). Of the two non-responders,
one was Ad5-seronegative and the other was Ad5-seropositive.
These unexpected results indicated that Ad5 serostatus was not
correlated to the Ad5-specific cellular IFN-c response based on
our pre-defined positivity criteria for each assay (Fisher’s exact test,
p=1.0). The only analyte that had a significant correlation
between Ad5-specific cellular response rate and Ad5 serostatus was
IL-17, which displayed an 87.5% response rate in the Ad5-
seropositive test group (7/8) compared to a 35.3% response rate in
the Ad5-seronegative group (6/17, Fishers exact test, p=0.03;
data not shown).
We next compared the Ad5-specific response profile at baseline
to the profile from the peak immunogenicity timepoint and
observed that a similar profile of cytokines was produced at both
time points (Figures 1A, lower panel and Figure 3). Using the same
criteria for determining a focused set of significantly up-regulated
cytokines employed for the peak timepoint samples (i.e., greater
than 50% response rate and greater than two-fold significant up- or
down-regulationcomparedto controls),wefound the same subsetof
11 cytokines was selected at baseline as for the peak timepoints, and
also observed that the relative levels of each cytokine in baseline
samples were the same as in the peak time point samples. The
defining characteristics of these similar cytokine profiles were that
IFN-c, IP-10, and IL-2 were produced in the greatest measured
responses at baseline, followed in order by IL-13, sCD40L, IL-10,
MIP-1b, GM-CSF, TNF-a, IL-17, and IL-1Ra (Figure 3). The
cytokines absent from the peak timepoint responses were also not
significantly up-regulated in baseline samples.
Blunted Ad5-specific cellular responses correlate with
boosted Ad5 neutralizing antibodies
After examining the naturally-occurring Ad5-specific immunity
in vaccine recipients, we compared the overall (independent of
Ad5 serostatus) concentrations of secreted cytokines from baseline
and peak timepoint samples following Ad5 stimulation. We
unexpectedly saw significantly higher concentrations of IFN-c
(p=0.01), IL-10 (p=0.02), IL-1Ra (p=0.02), and GM-CSF
(p=0.005) were secreted from baseline samples when compared
to peak time point samples (Figure 2B). We also observed a trend
toward higher concentrations of TNF-a at baseline compared to
the peak timepoint, but this difference was not statistically
significant (p=0.08). To determine if the cellular response to
Ad5 empty vector following vaccination was more markedly
reduced in vaccine recipients with pre-existing Ad5 neutralizing
antibodies versus those without, we stratified our analysis into
Ad5-seronegative and Ad5-seropositive test groups as described
above. We found that PBMC from Ad5-seropositive vaccine
recipients stimulated with Ad5 empty vector at baseline secreted
four times more IFN-c (median 1067 pg/ml vs. 267 pg/ml;
p=0.005) and GM-CSF (250 vs. 57 pg/ml; p=0.02), and nearly
twice much IL-2 (106 vs. 67 pg/ml; p=0.02) compared to after
vaccination (Figure 2B). In addition, we observed that PBMC from
Ad5-seropositive vaccinees secreted two-to-four times less TNF-a
(63 vs. 32 pg/ml; p=0.08), IL-13 (158 vs. 55 pg/ml; p=0.08),
and IP-10 (1834 vs. 433 pg/ml; p=0.07) after vaccination, but
these latter results were not statistically significant (Figure 2B).
Conversely, pre-vaccination PBMC from Ad5-seronegative vac-
cine recipients stimulated with Ad5 empty vector secreted about
half as much IL-10 when compared to post-vaccination PBMC
(545 vs. 1095 pg/ml, respectively; p=0.05), but the levels of IFN-
c, IL-2, and GM-CSF did not differ in these comparisons.
To test if the observed decrease in Ad5-specific cytokine
production from PBMC following vaccination was related to
increased humoral responses against the MRKAd5 HIV-1 gag
vaccine, we measured the Ad5 neutralizing antibody titers in the
test subjects from the baseline time point through 78 weeks of
study follow-up. We observed that the median Ad5 neutralizing
antibody titer was about six times higher in Ad5-seropositive group
than the Ad5-seronegative group at the peak vaccine response
Figure 3. Frequency and magnitude of Ad5-stimulated cellular responses of vaccinees prior to vaccination. PBMC collected from trial
participants prior to vaccination (baseline) were tested by multiplex cytokine assay. Magnitudes of response for 30 analytes tested are expressed as
log10 fold change over background for Ad5-seronegative (n=17, blue triangle) and Ad5-seropositive (n=8, red triangle) volunteers. Non-responders
are shown in gray. Box and whisker plots indicate median and interquartile ranges for responders only, while connecting line illustrates overall profile
for comparison.
doi:10.1371/journal.pone.0018526.g003
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Over the course of the 78-week follow-up period, the median
difference in Ad5 neutralizing antibody titer ranged from six to 28
times higher in the Ad5-seropositive group and delineated
differing plateaus based on pre-existing Ad5 neutralizing antibody
levels. This contrasts with our results showing that Th1-associated
cellular responses to the Ad5 vector were significantly lowered in
the Ad5-seropositive group, but not the Ad5-seronegative group
following vaccination.
Altogether, our results show that the cytokine profile of Gag-
specific T-cell responses is remarkably similar to the vector-specific
immunity that is present prior to vaccine administration, and the
magnitude of insert-specific cytokine responses was associated with
both humoral and cellular immune responses to the Ad5 vector.
Discussion
The results of pre-clinical studies and the Step Study clearly
indicate that more investigation is needed to clarify how pre-
existing vector immunity can affect the outcome of vaccination
against HIV-1 [1,4]. We addressed this need in part by conducting
a thorough evaluation of the insert- and vector-specific cytokine
responses to an Ad5-HIV-1 Gag vaccine candidate similar to that
used in the Step Study. Although recent studies have demonstrated
that differences in Ad5-specific cellular immunity can affect
vaccine-induced T-cell responses [2,23], to our knowledge this is
the first comprehensive analysis of HIV-1 vaccine-induced T-cell
responses that has examined more than a few select cytokines. By
surveying an extensive cytokine profile of antigen-specific T cells,
we were able to observe that, in addition to IFN-c, IL-2, and TNF-
a, MRKAd5 HIV-1 gag vaccination induced Gag-specific T cells
that secreted IP-10, IL-10, IL-13, sCD40L, GM-CSF, MIP-1b,
IL-1Ra, and IL-17, most of which have not been previously
related to HIV-1 vaccine-induced responses.
The remarkably similar cytokine profiles we observed in
response to the Gag insert and the Ad5 vector suggests that the
immune response to the vector will be predictive of the quality of
T-cell response to the delivered immunogen. While the converse
could not be formally ruled out in this study, other studies have
shown that vector differences influence the type of immune
response to an inserted transgene [4,24,25,26]. In addition, our
finding that the Ad5-specific cytokine profile is present prior to
vaccination indicates that the type of response induced by a viral
vector vaccine may be pre-determined by a vaccine recipient’s
memory repertoire defined by natural exposures and inherited
HLA haplotype.
The lack of correlation between Ad5 serostatus and T-cell
responses at baseline has been reported recently in other studies, in
which increases in the frequency of IFN-c and/or IL-2-secreting
CD4
+ and/or CD8
+ T cells following Ad5/HIV vaccination in
subjects with pre-existing Ad5 neutralizing antibody titers were
also reported [23,27,28]. Of these studies, however, only one
report included Ad5-specific responses past week eight (four weeks
post-second vaccination), and that report’s authors observed that
the differences between Ad5 serostatus groups were transient and
resolved after a third dose of vaccine [27]. In addition, all of these
studies, including the present one, have only detected peripheral
immune responses and not assessed immune response at mucosal
surfaces or other sites of primary infection. It is likely that cross-
Figure 4. Ad5-specific neutralizing antibody titers before and after the MRKAd5 HIV-1 gag vaccine regimen. Serum samples collected
at regular intervals during the vaccination schedule from Ad5-seronegative (n=35, blue dots) and Ad5-seropositive (n=34, red dots) vaccine
recipients were assayed for Ad5 neutralizing antibody activity. Vaccination visits at 0, 4, and 26 weeks are indicated by green arrows. Bars indicate
median neutralizing titers for each group at a given time point.
doi:10.1371/journal.pone.0018526.g004
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detection of T-cell responses to Ad5 empty vector in the absence of
pre-existing Ad5 neutralizing antibodies, because there is signif-
icant conservation between members of adenovirus genera and a
small number have now been shown to be cross-reactive in
humans [28,29,30]. Although our data confirm the lack of
correlation between Ad5 serostatus and Ad5-specific T-cell
responses observed by others, in contrast to published reports we
observed that levels of certain cytokines, such as IFN-c, IL-10,
GM-CSF and IL-1Ra, were reduced following vaccination.
Furthermore, the levels of a different subset of cytokines (IL-2,
IL-10 and IP-10) were lower in Ad5-seropositive compared to
Ad5-seronegative vaccinees. This apparent disagreement with
others’ results may be due to the differences inherent in measuring
the frequency of cytokine-producing cells by ICS and ELISpot
versus measuring the actual amount of cytokine secreted by the
multiplex cytokine assay used in our study. In addition, this assay
as described is limited by the fact that it cannot distinguish
between CD4
+ and CD8
+ T-cell responses and only a single post-
stimulation timepoint was measured. Differences in assay charac-
teristics highlight the need to examine multiple endpoints in the
absence of a clear correlate of vaccine-induced immunity to HIV-
infection or disease progression. In addition, it is important to note
that differences we detected were not adjusted for any factors (e.g.,
age), and as expected, the significance levels were reduced after
multiple comparison adjustments. However, although the results
should be interpreted cautiously in consideration of the explor-
atory nature of this study, the overall conclusions of the study
remain sound.
In the case of Ad5-specific immunity, the observed cytokine
response profile was a complex mixture of Th1- and Th2-
associated cytokine responses, and the higher IL-10 levels observed
in response to the Ad5 empty vector compared to the Gag insert
may be indicative of an immunosuppressive characteristic
previously unrecognized in Ad5-based vaccine candidates or
possibly related to the innate ability of adenovirus to activate
macrophage and monocytes [31]. IL-10 is a pleiotropic immuno-
modulatory cytokine associated with immunosuppression that also,
in combination with IL-4, IL-5, and IL-13, skews immune
function in vivo towards a Th2 type of response [32]. The
observation that IL-13 was produced in the presence of IFN-c,
TNF-a, and IP-10, raises questions about the efficacy of HIV-
specific memory T-cell responses present when a mixture of Th1
and Th2 factors are engaged.
The additional contribution of IL-10 in this mixture of Th1 and
Th2 responses remains to be clarified, but may be critical in light
of recent studies that highlight a larger role of IL-10 in HIV-1
pathogenesis. In HIV-1 infected individuals, higher levels of IL-10
can blunt both the host T-cell response to HIV-1 and viral
replication in macrophages and dendritic cells, as well as promote
aberrant dendritic cell activity that may favor the virus [33,34,35].
Recent studies in mice have shown that blocking the IL-10
signaling pathway facilitates clearance of chronic viral infections
[36,37], and in vitro studies in PBMC from HIV-infected subjects
have extended these findings to indicate that HIV-specific CD4
+
and CD8
+ T-cell responses are also augmented by antibodies that
interrupt the IL-10/IL-10-receptor interaction [38]. Additional
evidence that IL-10 expression levels may be important in
providing protection against HIV-1 infection comes from the
observation that genetic polymorphisms in IL-10 coding and
promoter regions that are linked to higher IL-10 mRNA levels and
associated with accelerated HIV-1 disease progression [39,40]. In
light of these interactions, an IL-10/IL-10-receptor blockade has
been suggested as a potential adjunctive therapy for HIV-1
infection, with a proposed mechanism of viral clearance in the
production and maintenance of functional antigen-specific mem-
ory T cells [41]. Since interruption of the effects of this
immunosuppressive cytokine is beneficial for HIV-1 control,
higher levels of IL-10 secretion in response to Ad5 stimulation
may present a barrier to controlling of HIV-1 infection with Ad5-
vaccine-induced T cells.
The fact that a significantly higher amount of IP-10 was
produced in response to Gag peptides by PBMC from the Ad5-
seronegative group when compared to the Ad5-seropositive group
suggests that vaccine-induced antiviral cellular immunity may be
affected by the presence of vector-specific neutralizing antibodies.
IP-10 (interferon-c-inducible protein, 10 kiloDaltons or CXCL10)
is a chemoattractive cytokine which is rapidly produced in large
amounts in response not only to IFN-c, but also to other factors
such as Type I interferon and lipopolysaccharide (reviewed in
[42]). The fact that IP-10 production is most often seen in
conjunction with IFN-c presents the question of why IP-10 is the
only cytokine that has significantly different regulation between
vaccinees with or without pre-existing Ad5 immunity in our study.
Two possible explanations for this discrepancy are that differing
IP-10 levels are indicative of an antiviral amplification step that is
affected by Ad5-specific immunity via an unknown mechanism, or
alternatively, that vaccine-specific memory T cell populations may
be differentially polarized to Th-helper cell subsets by the pre-
existing vector-specific immunity. Support for the latter mecha-
nism comes from data showing that the IP-10 receptor, CXCR3, is
preferentially expressed on Th1-polarized cells in conjunction with
other Th1-associated chemokine receptors, such as CCR5 and
CCR2 [43]. Therefore, a decreased amount of IP-10 in Ad5-
seropositive vaccinees may indicate that T cells are more likely to
be polarized toward Th2, or other non-Th1 subtypes, such as the
Th17 response. A trend towards a greater fraction of Ad5-
seropositive than Ad5-seronegative volunteers producing IL-17 in
response to Ad5 empty vector before vaccination may be
indicative of such a Th17 polarization, but further studies will
be necessary to confirm this connection.
Other previously unrecognized vaccine-induced cytokine re-
sponses produced in significant quantities by Gag- and Ad5-
stimulated PBMC in our study were sCD40L (soluble CD40
ligand), IL-1Ra (interleukin-1 receptor antagonist), and GM-CSF
(granulocyte-monocyte colony stimulating factor, or colony
stimulating factor 2, [CSF2]). The net effect of this combination
of cytokines in response to an Ad5-HIV-1 vaccine is unclear, but
the individual contributions of each factor may provide clues.
Previous work has shown that CD40L acts as a potent maturation
agent for dendritic cell priming of antiviral CD8
+ T cells [44]; it
has recently been incorporated as an adjuvant for several viral
vector vaccine candidates with some success [45,46]. Whether or
not such augmentation with CD40L can offer greater protection in
an HIV/SIV challenge model has not been shown. Next, IL-1Ra
is secreted in response to HIV-1 by macrophages in vitro, and
increased plasma concentrations of IL-1Ra correlate with HIV-1
disease progression in vivo [47,48]. However, a recent study of pig-
tail macaques found IL-1Ra to be secreted at peak levels in the
genital tract and plasma immediately following vaginal SHIV
exposure, even if infection was not immediately productive [49].
This may indicate that innate stimulation of this immunosuppres-
sive cytokine represents an advantage to HIV-1, thus limiting the
production of IL-1Ra may be viewed as a beneficial outcome in
future vaccine candidates. Finally, GM-CSF, which has long been
associated with HIV-1 production in monocytes [50,51,52], was
more recently introduced as an adjunctive therapy for leukopenia
in HIV-1-infected individuals (reviewed in [53]) and was found to
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certain next-generation HIV-1 vaccine candidates [54,55].
Whether or not these cytokine responses can or should be
enhanced further to boost the efficacy of an HIV-1 T-cell vaccine
remains to be seen. However, this examination of the cytokine
profile induced by an Ad5-HIV-1 vaccine may serve as a
benchmark for comparing future vaccine candidates.
In contrast to the homologous prime-boost vaccine regimen
used in this study, a recent challenge experiment in rhesus
macaques showed that a heterologous prime-boost regimen with
differing adenovirus strains produced more polyfunctional mem-
ory T cell populations and significantly lowered set-point viral
loads [4]. Because of the cross-reactivity of cellular responses to
different adenoviruses, this effect is likely due to a lack of induced
humoral responses to the first vector administered (prime) that
cross-react with the second vector (boost) [28,29,30,56]. Although
a general blunting of insert-specific responses due to pre-existing
Ad5 immunity has been observed previously [57,58], the results of
our study extend this dampened response to cellular Ad5-specific
responses following three doses of the MRKAd5 HIV-1 gag
vaccine, while also demonstrating that the post-vaccination
magnitudes of both Ad5 neutralizing antibodies and cellular
responses are correlated with previous Ad5 exposure. Together,
these results suggest that limiting vector exposures by administer-
ing fewer inoculations may be preferable, either with or without a
heterologous prime, when designing a vaccine regimen.
Because IFN-c, IL-2, and TNF-a production represent the
canonical antiviral Th1 response, they are believed to be integral
and necessary components of an effective anti-HIV-1 T-cell
response. Although such responses may well be necessary, they are
not sufficient to mitigate HIV-1 disease, as relatively high response
rates and magnitudes of these cytokines were observed in the HIV-
infected Step Study participants but they did not correlate with
any observed reduction in viral load. By measuring the magnitude
of an expanded panel of cytokines in future HIV-1 vaccine trials,
we may find that protective immune responses are correlated with
positive disease outcomes. Continuing to investigate immune
parameters such as these will lead to a better understanding of the
immune correlates of protection against HIV-1 disease progression
and, hopefully, to an effective HIV-1 vaccine.
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